Wright State University

CORE Scholar
Pediatrics Faculty Publications

Pediatrics

5-1-2014

Pharmacokinetics and pharmacodynamics of antifungals in
children and their clinical implications
Chris Stockmann
Jonathan E. Constance
Jessica K. Roberts
Jared Olson
Elizabeth H. Doby

See next page for additional authors

Follow this and additional works at: https://corescholar.libraries.wright.edu/pediatrics
Part of the Pediatrics Commons

Repository Citation
Stockmann, C., Constance, J. E., Roberts, J. K., Olson, J., Doby, E. H., Ampofo, K., Stiers, J., Spigarelli, M. G.,
& Sherwin, C. M. (2014). Pharmacokinetics and pharmacodynamics of antifungals in children and their
clinical implications. Clinical pharmacokinetics, 53 (5), 429-454.
https://corescholar.libraries.wright.edu/pediatrics/681

This Article is brought to you for free and open access by the Pediatrics at CORE Scholar. It has been accepted for
inclusion in Pediatrics Faculty Publications by an authorized administrator of CORE Scholar. For more information,
please contact library-corescholar@wright.edu.

Authors
Chris Stockmann, Jonathan E. Constance, Jessica K. Roberts, Jared Olson, Elizabeth H. Doby, Krow
Ampofo, Justin Stiers, Michael G. Spigarelli, and Catherine MT Sherwin

This article is available at CORE Scholar: https://corescholar.libraries.wright.edu/pediatrics/681

HHS Public Access
Author manuscript
Author Manuscript

Clin Pharmacokinet. Author manuscript; available in PMC 2017 August 21.
Published in final edited form as:
Clin Pharmacokinet. 2014 May ; 53(5): 429–454. doi:10.1007/s40262-014-0139-0.

Pharmacokinetics and Pharmacodynamics of Antifungals in
Children and their Clinical Implications
Chris Stockmann,
Division of Clinical Pharmacology, Department of Paediatrics, University of Utah School of
Medicine, 295 Chipeta Way, Salt Lake City, UT 84108, USA

Author Manuscript

Division of Infectious Diseases, Department of Pediatrics, University of Utah School of Medicine,
Salt Lake City, UT, USA
Department of Pharmacology/Toxicology, University of Utah, College of Pharmacy, Salt Lake City,
UT, USA
Jonathan E. Constance,
Division of Clinical Pharmacology, Department of Paediatrics, University of Utah School of
Medicine, 295 Chipeta Way, Salt Lake City, UT 84108, USA
Jessica K. Roberts,
Division of Clinical Pharmacology, Department of Paediatrics, University of Utah School of
Medicine, 295 Chipeta Way, Salt Lake City, UT 84108, USA

Author Manuscript

Jared Olson,
Division of Infectious Diseases, Department of Pediatrics, University of Utah School of Medicine,
Salt Lake City, UT, USA
Pharmacy, Primary Children’s Hospital, Intermountain, Healthcare, Salt Lake City, UT, USA
Elizabeth H. Doby,
Division of Infectious Diseases, Department of Pediatrics, University of Utah School of Medicine,
Salt Lake City, UT, USA
Krow Ampofo,
Division of Infectious Diseases, Department of Pediatrics, University of Utah School of Medicine,
Salt Lake City, UT, USA

Author Manuscript

Justin Stiers,
Division of Neonatology, Department of Pediatrics, University of Utah School of Medicine, Salt
Lake City, UT, USA
Michael G. Spigarelli, and
Division of Clinical Pharmacology, Department of Paediatrics, University of Utah School of
Medicine, 295 Chipeta Way, Salt Lake City, UT 84108, USA

Correspondence to: Catherine M. T. Sherwin.
Transparency Declarations The authors declare that they have no conflicts of interest.
Contributors CS, JEC, JKR, MGS and CMTS developed the review and wrote the initial draft of the manuscript. Additionally, all
authors contributed substantively to the review and revision of the final version.

Stockmann et al.

Page 2

Author Manuscript

Department of Pharmacology/Toxicology, University of Utah, College of Pharmacy, Salt Lake City,
UT, USA
Catherine M. T. Sherwin
Division of Clinical Pharmacology, Department of Paediatrics, University of Utah School of
Medicine, 295 Chipeta Way, Salt Lake City, UT 84108, USA

Abstract

Author Manuscript
Author Manuscript
Author Manuscript

Invasive fungal infections are a significant cause of morbidity and mortality in children. Successful
management of these systemic infections requires identification of the causative pathogen,
appropriate antifungal selection, and optimisation of its pharmacokinetic and pharmacodynamic
properties to maximise its antifungal activity and minimise toxicity and the emergence of
resistance. This review highlights salient scientific advancements in paediatric antifungal
pharmacotherapies and focuses on pharmacokinetic and pharmacodynamic studies that underpin
current clinical decision making. Four classes of drugs are widely used in the treatment of invasive
fungal infections in children, including the polyenes, triazoles, pyrimidine analogues and
echinocandins. Several lipidic formulations of the polyene amphotericin B have substantially
reduced the toxicity associated with the traditional amphotericin B formulation. Monotherapy with
the pyrimidine analogue flucytosine rapidly promotes the emergence of resistance and cannot be
recommended. However, when used in combination with other antifungal agents, therapeutic drug
monitoring of flucytosine has been shown to reduce high peak flucytosine concentrations, which
are strongly associated with toxicity. The triazoles feature large inter-individual pharmacokinetic
variability, although this pattern is less pronounced with fluconazole. In clinical trials,
posaconazole was associated with fewer adverse effects than other members of the triazole family,
though both posaconazole and itraconazole display erratic absorption that is influenced by gastric
pH and the gastric emptying rate. Limited data suggest that the clinical response to therapy may be
improved with higher plasma posaconazole and itraconazole concentrations. For voriconazole,
pharmacokinetic studies among children have revealed that children require twice the
recommended adult dose to achieve comparable blood concentrations. Voriconazole clearance is
also affected by the cytochrome P450 (CYP) 2C19 genotype and hepatic impairment. Therapeutic
drug monitoring is recommended as voriconazole pharmacokinetics are highly variable and small
dose increases can result in marked changes in plasma concentrations. For the echinocandins, the
primary source of pharmacokinetic variability stems from an age-dependent decrease in clearance
with increasing age. Consequently, young children require larger doses per kilogram of body
weight than older children and adults. Routine therapeutic drug monitoring for the echinocandins
is not recommended. The effectiveness of many systemic antifungal agents has been correlated
with pharmacodynamic targets in in vitro and in murine models of invasive candidiasis and
aspergillosis. Further study is needed to translate these findings into optimal dosing regimens for
children and to understand how these agents interact when multiple antifungal agents are used in
combination.

1 Introduction
Invasive fungal infections are a leading cause of mortality among immunocompromised and
critically ill children [1]. The most common aetiological agents of invasive fungal infections
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are Candida and Aspergillus, which despite prompt antifungal therapy have mortality rates
of 30–80 % [2–6]. It is therefore desirable to consider antifungal pharmacokinetics and
pharmacodynamics, which have the potential to inform the development of dosing regimens
that can improve antifungal activity and minimize toxicity [7].
Currently, four broad classes of systemic antifungal agents are used in the treatment of
invasive fungal infections, including the polyenes, triazoles, pyrimidine analogues, and
echinocandins [8]. The polyenes and triazoles target key components of the fungal cell
membrane (Fig. 1) [9]. The pyrimidine analogue flucytosine inhibits DNA and RNA
synthesis, which disrupts protein synthesis and cellular division [10]. The echinocandins are
a recently discovered class of antifungal agents that interfere with cell wall biosynthesis
[11]. Each of these classes exhibits unique pharmacokinetic and pharmacodynamic
characteristics, which have been the subject of varying degrees of scientific investigation.

Author Manuscript
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Pharmacokinetic and pharmacodynamic relationships have been defined for several
antifungal agents that have been used to predict responses to treatment [12, 13]. In
evaluating these pharmacodynamic relationships, three patterns of antifungal activity have
been defined: (1) concentration-dependent activity, where antifungal activity increases with
higher drug concentrations (e.g. polyenes and echinocandins); (2) time-dependent activity
with little to no post-antifungal effect, where higher antifungal concentrations do not
increase the rate or extent of antifungal activity and there is negligible antifungal activity
when drug concentrations fall below the minimum inhibitory concentration (MIC) (e.g.
flucytosine); and (3) time-dependent activity with prolonged post-antifungal effects, where
fungal growth is suppressed for a period of time after the drug concentration falls below the
MIC (e.g. triazoles) [14, 15]. However, it must be noted that post-antifungal effects are often
pathogen specific [16, 17]. To define the pharmacodynamic pattern that best describes the
antifungal activity of a given drug dose fractionation studies are often performed, in which a
variety of doses are administered at multiple dosing intervals (Fig. 2). If regimens with
shorter dosing intervals are more efficacious, then the time-dependent pharmacodynamic
parameter (T > MIC) is the most important parameter, as in the case of flucytosine [12].
When large, infrequently administered doses are the most efficacious, then the ratio of the
maximum concentration (Cmax) to the MIC (Cmax)/MIC) is the most important
pharmacodynamic parameter, as in the case of the polyenes and echinocandins [15, 18, 19].
Lastly, when antifungal activity is comparable for each of the dosing intervals, then the
clinical outcome is most dependent on the total dose or the area under the plasma
concentration–time curve (AUC) in relation to the MIC (AUC/MIC) [20]. Dose fractionation
studies have found that this pattern of activity is correlated with the clinical response to
therapy for the triazoles [13, 21]. Both in vivo and in vitro experiments have shown that the
pharmacodynamic parameter that is best correlated with the response to treatment and its
relative magnitude are comparable for drugs within the same class, when unbound drug
concentrations are evaluated [22]. Additionally, extensive studies conducted with
antibacterials have demonstrated that the correlation between pharmacodynamic target
attainment and clinical outcomes is remarkably conserved across species, dosing intervals
and infection foci [22, 23]. This may reflect the fact that the targets of antimicrobial
therapies are within the infecting organism and thus do not vary as a consequence of
differing host species [24]. Additionally, pharmacodynamic targets are often formulated as a
Clin Pharmacokinet. Author manuscript; available in PMC 2017 August 21.
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function of the unbound drug concentration and therefore account for inter- and intra-species
pharmacokinetic differences [24].
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For well-studied conditions, such as disseminated candidiasis, a bridging approach has
proven effective in extending results obtained from studies conducted in animal models to
the clinic [25]. For children, this often involves extrapolation of efficacy from studies in
adults [26]. Recent guidelines from the US FDA and the European Medicines Agency
(EMA) have recognised that this approach may be considered in cases where the drug is to
be used for the same indication(s), the disease process is similar, and the outcome of therapy
is comparable. Successful examples can be found in the field of antifungal pharmacology
with respect to the development of caspofungin and micafungin [27, 28]. These drugs were
licensed for paediatric use following a series of systematic investigations in phase I–III
clinical trials, which established age-specific population pharmacokinetics, determined
appropriate paediatric doses, and collected limited safety and efficacy data needed to support
the feasibility of extrapolating data from large randomised trials conducted in adults [29–
31]. Despite these and other recent successes, many of the older antifungal agents have never
been licensed for paediatric use and remain understudied. A list of antifungal agents that
have been approved by the FDA for the treatment of invasive fungal infections is featured in
Table 1.

Author Manuscript

Understanding the pharmacokinetics and pharmacodynamics of antifungal agents used
across the paediatric age spectrum represents a major challenge as human growth during the
first two decades of life is dynamic and nonlinear [32]. For the safe and effective treatment
of invasive fungal infections it is necessary to evaluate drug absorption, distribution,
metabolism and elimination throughout childhood [33]. In this review, we comprehensively
evaluate the pharmacokinetic and pharmacodynamic literature describing the four most
common classes of antifungal agents and describe paediatric-specific considerations in their
pharmacokinetics, pharmacodynamics and therapeutic drug monitoring. Each section
concludes with an evaluation of current knowledge gaps and highlights areas for future
research. Published reports were systematically identified using the search terms ‘paediatric’
or ‘pediatric’ or ‘children’ and the generic and trade names for each antifungal agent in
PubMed and EBSCOhost. When no paediatric studies were identified, the query was
modified to remove the paediatric-specific search terms. Identified articles were then
reviewed and evaluated by at least two authors and duplicate publications were excluded
from further review. The literature search was finalised on 1 November 2013 and no limits
were applied on the basis of publication date.

Author Manuscript

2 Polyenes
Polyene macrolides are the oldest class of antifungal agents and have been used for more
than 50 years, primarily due to their broad spectrum of activity [34–36]. The most common
systemically administered drug in this class is amphotericin B deoxycholate [37].
Amphotericin B binds to fungal membrane ergosterols, which results in increased cell
permeability and ultimately cell death [38]. Although amphotericin B binds to fungal
membrane sterols with high affinity, it also binds to cholesterol components of mammalian
cells and therefore is commonly associated with toxic adverse events [36].
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In an effort to alleviate concerns regarding toxicity, several lipid-based formulations of
amphotericin B have been developed [39]. The reformulation of amphotericin B into a
liposomal carrier (liposomal amphotericin B) or a lipid complex with a ribbon-like
(amphotericin B lipid complex) or disk-like (amphotericin B colloidal dispersion) shape
alters the pharmacokinetic and pharmacodynamic properties of these drugs. Critically, in
comparison to conventional amphotericin B deoxycholate, these three commercially
produced lipidic formulations are associated with less toxicity [37].
2.1 Pharmacokinetics and Pharmacodynamics

Author Manuscript

Amphotericin B deoxycholate is administered parenterally as it exhibits negligible
gastrointestinal absorption [38]. Upon entering the bloodstream, amphotericin B rapidly
dissociates from the deoxycholate, where >90 % of the drug binds to serum proteins [38].
Amphotericin B distributes widely into tissues, particularly the liver and spleen (Table 2)
[40]. In adults, amphotericin B features a distribution phase of 15–48 h and a terminal
elimination half-life of approximately 15 days [41]. Similar distribution phase kinetics have
been reported for pre-term neonates, infants, and children 4 months to 14 years of age [42,
43]. Among children, the terminal elimination phase half-life of amphotericin B has been
reported to range from weeks to months [42]. Amphotericin B poorly penetrates into the
cerebrospinal fluid (CSF), vitreous humour or amniotic fluid [44]. Excretion into the urine is
also negligible [38].
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The clinical utility of amphotericin B deoxycholate is limited due to the drug’s narrow
therapeutic window, which requires clinicians to carefully balance efficacy and toxicity [39].
Adverse events commonly include acute infusion-related toxicity and nephrotoxicity [45,
46]. Within the last 10 years, several studies demonstrated that continuous infusion of
amphotericin B deoxycholate may reduce the incidence of nephrotoxicity and infusionrelated adverse reactions [47–51]. However, amphotericin B has been shown to feature
concentration-dependent antifungal activity in vitro, which suggests that infrequent
administration of large amphotericin B doses may optimise its pharmacodynamic activity
[15]. Moreover, amphotericin B exhibits non-linear, concentration-dependent protein
binding in plasma and tissues [52]. Few pharmacokinetic and pharmacodynamic studies
have accounted for the influence of physiologically relevant concentrations of human serum
albumin when comparing amphotericin B dosing regimens. However, in the single study
conducted to date, Lewis et al. [53] developed an in vitro pharmacodynamic model to
compare continuous versus rapid infusion strategies with varying concentrations of human
serum albumin. The authors found that the antifungal activity of amphotericin B was
dramatically reduced or completely ablated in the presence of human serum albumin
concentrations ranging from 4 to 8 %. The authors further reported no difference in the rate
or extent of amphotericin B antifungal activity with rapid or continuous infusion regimens.
These findings suggest that extended or continuous infusion strategies may reduce the
incidence of toxic adverse events, although such regimens are unlikely to optimise
amphotericin B pharmacodynamics and may result in treatment failure.
For patients who are refractory to or intolerant of conventional amphotericin B
deoxycholate, several lipidic formulations may be considered. The pharmacokinetic

Clin Pharmacokinet. Author manuscript; available in PMC 2017 August 21.

Stockmann et al.

Page 6

Author Manuscript

properties of these lipid-based formulations differ markedly when compared to amphotericin
B deoxycholate [38].
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Amphotericin B lipid complex pharmacokinetics have been extensively studied in mice, rats,
rabbits and dogs [54, 55]. Following administration of a single dose of amphotericin B lipid
complex, amphotericin B concentrations were substantially lower in the liver, spleen and
lungs than concentrations measured following administration of amphotericin B
deoxycholate [55]. Comparable concentrations were measured in the kidneys [55]. In
plasma, amphotericin B lipid complex achieved higher amphotericin B concentrations than
conventional amphotericin B deoxycholate [55]. As the dose of amphotericin B lipid
complex is increased, amphotericin B concentrations in the liver, spleen and lung tissue
increase markedly; however, no change is observed in amphotericin B concentrations in the
kidneys or in the plasma [55]. In a murine model system, the half-maximal lethal dose
(LD50) following a single intravenous dose of amphotericin B deoxycholate was determined
to be 3 mg/kg, whereas the LD50 of amphotericin B lipid complex was established at 40
mg/kg [56]. In multiple-dose studies, amphotericin B lipid complex continued to exhibit
significantly reduced toxicity in mice and rabbits when compared to amphotericin B
deoxycholate [56, 57]. In humans, the pharmacokinetics of amphotericin B lipid complex
are similar to those reported in animal studies [58].

Author Manuscript

Amphotericin B colloidal dispersion pharmacokinetics have also been extensively studied in
animal models [59–61]. Following a single intravenous bolus, amphotericin B colloidal
dispersion resulted in significantly lower plasma amphotericin B concentrations than dosing
with amphotericin B deoxycholate in rats [59]. The terminal elimination half-life is also
longer and the volume of distribution is considerably larger [59]. In dogs, administration of
amphotericin B colloidal dispersion resulted in increased amphotericin B concentrations in
the liver, comparable concentrations in the plasma and decreased concentrations in the
kidney when compared with dosing with amphotericin B deoxycholate [60]. In further
single- and multiple-dose experiments across several species, amphotericin B colloidal
dispersion consistently demonstrated less toxic effects than amphotericin B deoxycholate
[61]. As yet, few human trials have investigated the pharmacokinetics of amphotericin B
colloidal dispersion; however, safety and efficacy trials have demonstrated that amphotericin
B colloidal dispersion displays comparable antifungal activity and less nephrotoxicity than
amphotericin B at clinically relevant doses [62].

Author Manuscript

The pharmacokinetics of liposomal amphotericin B have been studied in mice, rats and
rabbit models of invasive fungal infection [63, 64]. Liposomal amphotericin B is negatively
charged and considerably smaller than the two lipid complex formulations of amphotericin
B (amphotericin B lipid complex and amphotericin B colloidal dispersion), which may
retard its uptake within the reticuloendothelial system [65]. This may explain, in part, why
liposomal amphotericin B achieves far higher peak amphotericin B plasma concentrations
and features a prolonged circulation time when compared to amphotericin B lipid complex
and amphotericin B colloidal dispersion [65]. In mice and rats, liposomal amphotericin B is
less nephrotoxic, with an LD50 50-fold lower than that of amphotericin B deoxycholate [63].
However, slight elevations in liver transaminases have also been reported following the
administration of multiple doses of liposomal amphotericin B [63]. In a small human
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autopsy study, liposomal amphotericin B achieved the highest amphotericin B
concentrations in the liver and the spleen, which is consistent with previous findings from
animal models [66]. Using a two-compartment model, liposomal amphotericin B
pharmacokinetic parameters were established for a cohort of 44 immunocompromised adults
[67]. The authors found that liposomal amphotericin B exhibits a non-linear dose-response
relationship that was consistent with reticuloendothelial uptake and redistribution [67]. Hong
et al. [68] evaluated the population pharmacokinetics of liposomal amphotericin B among 39
children with neoplastic disease and found that weight exerted a significant influence upon
both clearance and the volume of distribution in the central compartment. In simulations, the
authors found that weight-related changes in liposomal amphotericin B pharmacokinetic
parameters alter drug exposure, such that children <20 kg require a higher dose to achieve
peak amphotericin B concentration targets.

Author Manuscript

2.2 Intra- and Inter-Individual Variability
The disposition of amphotericin B deoxycholate is more variable among neonates and young
children than in adolescents and adults [69]. Serum half-lives were reported to be longer in
four of five neonates than in older children [69]. Following 5 days of therapy, interindividual variability in amphotericin B clearance was high among 13 neonates [42].
Pharmacokinetic evaluations conducted with amphotericin B lipid complex also revealed
evidence of substantial inter-individual variability in clearance and volume of distribution
(35 and 43 %, respectively) [70]. These data suggest that younger children have a greater
potential for drug accumulation and heightened inter-individual variability than adults [37].
Additionally, amphotericin B deoxycholate CSF concentrations are 2–4 % of serum
concentrations in adults; however, CSF penetration may be as high as 40 % among pre-term
neonates [42, 71].

Author Manuscript

2.3 Dosing Optimisation
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Amphotericin B features a broad spectrum of activity and is an established agent in the
treatment of endemic and opportunistic invasive fungal infections; however, up to 80 % of
patients experience infusion-related toxicity or nephrotoxicity [36, 72]. Although
nephrotoxicity is typically less severe in infants and children, efforts are needed to optimise
the dosing of amphotericin B to improve its tolerability [37]. To this end, several studies
have administered amphotericin B deoxycholate by continuous infusion, as opposed to
traditional 2–6 h infusions [49, 51, 73, 74]. These studies reported a decrease in the rate of
nephrotoxicity and fewer infusion-related reactions when compared with a 4-h infusion at
the same daily dose [51]. Despite these promising findings, however, continuous infusion of
amphotericin B has not been widely adopted due to challenges in obtaining venous access
solely for the purpose of administering the drug and pharmacodynamic data that suggest that
amphotericin B is most efficacious when higher daily doses are administered less frequently
[15, 24, 51].
In an effort to enhance the efficacy of amphotericin B dosing regimens, the randomised
multicentre AmBiLoad trial evaluated a high loading dose of liposomal amphotericin B at 10
mg/kg/day for the first 14 days of therapy as compared with standard dosing regimens of 3
mg/kg/day [75]. At the end of study drug treatment, the primary endpoint was assessed as
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complete or partial response to therapy, along with secondary survival and safety outcomes.
The authors found that liposomal amphotericin B at 3 mg/kg/day yielded a response rate of
50 % and a 12-week survival rate of 72 %. The high loading dose regimen did not improve
clinical outcomes and resulted in higher rates of nephrotoxicity.
2.4 Therapeutic Drug Monitoring
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Therapeutic drug monitoring for amphotericin B deoxycholate is of limited utility due to the
absence of a well-defined correlation between measured amphotericin B concentrations and
clinical efficacy [76]. Moreover, at doses that are routinely administered clinically, plasma
concentrations rarely exceed 1–2 μg/mL [77]. On the basis of these findings, in 1991 the
Working Party of the British Society for Antimicrobial Chemotherapy concluded that
therapeutic drug monitoring of amphotericin B deoxycholate is unnecessary [78]. More
recent studies have sought to determine whether plasma or serum amphotericin B
concentrations correlate with nephrotoxicity [79, 80]. These studies concluded that
amphotericin B-induced nephrotoxicity was correlated with the total cumulative dose, rather
than serum concentrations. To date, amphotericin B plasma or serum concentrations have
not been correlated with clinical efficacy or toxicity, such that therapeutic drug monitoring
cannot be recommended. Limited paediatric pharmacokinetic data suggest that the intraindividual variability observed with the lipidic formulations of amphotericin B may be larger
than the inter-individual variability, confounding dose individualisation efforts through
therapeutic drug monitoring [68, 81].
2.5 Drug Resistance
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Despite more than 50 years of widespread clinical use, fungal resistance to amphotericin B
is rare [82]. In a recent study of more than 9,000 Candida albicans isolates, 99.8 % remained
sensitive to amphotericin B [83]. Resistance is most frequently encountered in isolates of
Candida lusitaniae, Aspergillus terreus and Aspergillus nidulans [84]. In in vitro
experiments, mutant isolates that display resistance to amphotericin B and nystatin develop
compensatory mechanisms to replace ergosterol with precursor sterols [85]. Due to the
relative scarcity of polyene-resistant fungal strains, it has been speculated that the fitness
cost incurred by developing this adaptive form of resistance attenuates the pathogenicity of
ergosterol-deficient mutants [86].
2.6 Clinical Recommendations and Prospects for Future Research
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As equally effective, less toxic antifungal agents have been developed, it is now unlikely that
further characterisation of amphotericin B deoxycholate pharmacokinetics and
pharmacodynamics will occur [87]. However, further evaluation of lipidic formulations of
amphotericin B is warranted due to their improved toxicity profile and equivalent efficacy
[88, 89]. These agents are typically employed as salvage therapies for patients who are
refractory to or intolerant of amphotericin B deoxycholate, primarily owing to their high
cost. Consequently, few studies have sought to establish correlations between
pharmacokinetic profiles and clinical outcomes. As the costs of these agents decrease, such
studies will be invaluable in guiding clinical decision making.

Clin Pharmacokinet. Author manuscript; available in PMC 2017 August 21.

Stockmann et al.

Page 9

Author Manuscript

3 Pyrimidine Analogues
Flucytosine (5-fluorocytosine, 5-FC) is a pro-drug that is actively transported into fungal
cells by cytosine permease [90]. Cytosine deaminase converts flucytosine to 5-fluorouracil,
which can subsequently be converted to 5-fluorouridine triphosphate for incorporation
within fungal RNA (thereby inhibiting protein synthesis), or be converted to 5fluorodeoxyuridine monophosphate and inhibit thymidylate synthetase (thereby inhibiting
DNA synthesis) [10, 91, 92].
3.1 Pharmacokinetics and Pharmacodynamics
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Flucytosine is administered orally with >70 % absorption, although absorption can be
delayed by renal insufficiency, antacids and food [93, 94]. Flucytosine is not highly bound
by serum proteins, is highly water soluble, and penetrates well into the CSF, vitreal humour,
peritoneal fluid as well as the synovial fluid of inflamed joints [93, 95–98]. Peak
concentrations are reached within 1–2 h post-administration and it is recommended that
serum concentrations be maintained between 40 and 80 μg/mL [93, 99]. Flucytosine is
primarily eliminated by the kidneys via glomerular filtration, such that its clearance is
closely correlated with serum creatinine concentrations [93, 97, 100].
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Flucytosine is rarely used as a monotherapy due to the emergence of rapid antifungal
resistance during treatment [101–105]. However, flucytosine is thought to be synergistic
with amphotericin B, which facilitates its penetration into fungal cells [106]. Concentrations
of amphotericin B are increased in the CSF, heart valves and the vitreal body when
coadministered with flucytosine [101]. There are sparse pharmacokinetic data on flucytosine
in paediatric patients. In adults, the serum half-life of flucytosine is 3–6 h in patients with
normal renal function, but is extended in patients with impaired renal function (up to 85 h)
[97]. A neonatal pharmacokinetic study demonstrated that the half-life was twice that
reported in adults, although peak concentrations were comparable [42]. Additionally, the
volume of distribution of flucytosine approximates the volume of total body water due to its
high solubility [103]. In a retrospective study of 391 paediatric patients, 65 % of flucytosine
trough concentrations exceeded the normal reference range in children 1–30 days of age
[107]. These data suggest that the standard dose of 100 mg/kg/day may not be appropriate
and that further studies are needed to establish optimal age-appropriate dosing regimens.
3.2 Intra- and Inter-Individual Variability
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High inter-individual variability exists with paediatric patients. Baley et al. [42] reported that
three infants had an extended half-life up to 35 h, which they attributed to immature kidney
function.
3.3 Dosing Optimisation
Due to the prolonged half-life of flucytosine in paediatric patients, it has been suggested that
dosing intervals can be as long as 24 h without compromising its fungistatic activity, despite
adult recommendations for 6-hourly dosing [42]. Additionally, the synergistic effect of
amphotericin B and flucytosine achieves the same therapeutic target with lower doses [10,
108].
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When using flucytosine, it is important to monitor plasma concentrations to avoid toxicity.
High peak serum concentrations have resulted in hepatic injury, bone marrow suppression
and gastrointestinal disturbances [109–112]. In addition, renal insufficiency can be induced
by amphotericin B co-treatment and commonly leads to toxicity as a consequence of
decreased renal clearance.
3.5 Drug Resistance
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Resistance is common with flucytosine and typically occurs through mutations in cytosine
permease (decreases drug uptake into fungal cells), increased synthesis of pyrimidines
(decreases competitive inhibition) or, most commonly, through mutations in uridine
monophosphate pyrophosphorylase, which decrease the metabolism of flucytosine to its
active antimetabolite [94, 113, 114]. Both high and low flucytosine concentrations have been
demonstrated to incur resistance [114]. Nearly 8 % of C. albicans and Torulopsis glabrata
strains are intrinsically resistant, whereas only 1–2 % of Candida neoformans strains are
resistant [115]. Between 8 and 44 % of non-albicans Candida species have been reported to
be resistant to flucytosine [116].
3.6 Clinical Recommendations and Prospects for Future Research
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Flucytosine monotherapy is not recommended due to the rapid emergence of resistance and
therefore it is unlikely that feature studies will evaluate flucytosine pharmacokinetics in
isolation. However, further studies are needed in children to understand the mechanism and
effects of flucytosine and amphotericin B synergy. Pharmacokinetic and pharmacodynamic
studies will be vitally important in establishing an optimal dosing regimen for these two
agents [104]. Further investigation of combination therapies with triazoles is also warranted.

4 Triazoles
The triazoles feature broad antifungal activity and are well-tolerated [117]. These agents
interfere with fungal-specific cytochrome P450 (CYP) activity (lanosterol 14-αdemethylase), which then inhibits cell membrane ergosterol synthesis [118]. Ergosterol
synthesis is essential to maintain normal membrane permeability [119]. Triazole-mediated
inhibition of ergosterol synthesis alters fungal membrane permeability and results in cell
death.
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The most commonly prescribed triazole agents include fluconazole, itraconazole,
voriconazole and posaconazole [120]. Collectively, these drugs represent a major advance in
paediatric antifungal therapy, although historically their use has been marked by the
emergence of resistance and drug-drug interactions [117]. Fluconazole features activity
against many Candida species, but has little or no activity against Candida krusei, Candida
glabrata and most filamentous fungi, including Aspergillus [121]. Newer triazole agents,
such as posaconazole, display potent in vitro activity against pathogenic yeasts and moulds,
including fluconazole-resistant strains of Candida and Zygomycetes [122].
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Fluconazole is available for parenteral and oral administration and is well-absorbed from the
gastrointestinal tract (Table 3)[123]. Fluconazole is a hydrophilic drug and 11–13 % of the
drug binds to serum proteins [124, 125]. In adults, fluconazole distributes into a volume
similar to that of total body water (approximately 0.71 L/kg) [126]. However, the apparent
volume of distribution in immunocompromised paediatric patients varies by age, with the
largest volume of distribution reported among neonates, which decreases with increasing age
until adult levels are reached in adolescence [127]. Fluconazole is widely distributed to
nearly all organs and tissues, including the central nervous system (CNS) [119]. Fluconazole
also undergoes minimal metabolism and is primarily excreted unchanged in the urine [125,
128]. The longest half-life has been observed among neonates, which then declines to 21–23
h among children 3 months to 16 years of age and rises again to approximately 30 h among
adults [127, 129, 130]. These age-specific pharmacokinetic differences suggest that the
increased volume of distribution in children will result in lower systemic fluconazole
concentrations than in adults who receive a proportional dose [127]. Additionally, the shorter
half-life among children (with the exception of neonates) has the potential to result in
reduced drug accumulation if adult once-daily dosing regimens are extrapolated to children
[127].
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Itraconazole is available in a capsular, oral and intravenous formulation [131]. The capsular
formulation is characterised by erratic absorption and variable plasma concentrations [132].
More recently developed oral and intravenous formulations display less variable
pharmacokinetics [117]. Itraconazole is a highly lipophilic drug that is nearly insoluble in
water [133]. Gastric emptying rates affect itraconazole dissolution in the stomach and its
absorption from the small intestine [133]. Upon entering the bloodstream itraconazole
rapidly binds to red blood cells and circulating plasma proteins [134]. Consequently,
unbound concentrations of itraconazole in the CSF, vitreal fluid and saliva are markedly
lower than unbound plasma concentrations [134]. Following a single dose, peak
concentrations are reached within 2–3 h post-administration and the terminal elimination
half-life is approximately 25 h [135]. Itraconazole is extensively metabolised in the liver,
primarily by CYP3A4, for which itraconazole is both a substrate and an inhibitor [136]. Due
to CYP3A4 auto-inhibition, the half-life of itraconazole has been found to increase to more
than 30 h in patients following a week of therapy [137].
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Due to the highly variable absorption profile of the capsular formulation of itraconazole,
most paediatric studies have characterised the pharmacokinetics of the oral and intravenous
formulations of itraconazole [135, 138, 139]. de Repentigny and colleagues [138]
administered oral itraconazole at 5 mg/kg once daily for 2 weeks to 26 infants and children 6
months to 12 years of age who were at risk for invasive fungal infections. The authors
reported lower Cmax and AUC from time zero to 24 h (AUC24) values among children 6
months to 2 years of age on the first day of therapy, although these differences resolved by
day 14. When compared to repeated-dose pharmacokinetic studies among adults who
received oral itraconazole at 5 mg/kg, the Cmax and AUC24 among children were
approximately one third of the values measured among adults [138, 140, 141]. Similar
results were reported in a subsequent study conducted among 26 HIV-infected children and
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adolescents 5–18 years of age [135]. More recently, the single-dose pharmacokinetics of an
intravenous formulation of itraconazole were evaluated among 33 children 7 months to 17
years of age [139]. Itraconazole Cmax and AUC24 values were higher in children who
received the intravenous formulation than in previous studies conducted using the oral
formulation. However, as itraconazole undergoes significant first-pass hepatic inactivation
(approximately 50 %), this was not unexpected [142]. The authors found no evidence that
age influenced itraconazole pharmacokinetics, suggesting that weight-based dosing of
intravenous itraconazole may be employed irrespective of the age of the child being treated
[139].
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Voriconazole is available in both an oral and an intravenous formulation [143]. In healthy
volunteers, the oral formulation of voriconazole displays high bioavailability (>90 %) and
moderate protein binding (58 %) [144]. Unlike itraconazole, pharmacokinetic studies in
adults have revealed evidence of high inter-individual variability with both voriconazole
formulations [145, 146]. A non-linear dose-exposure relationship has been reported that may
be attributable to saturation of hepatic metabolizing enzymes [143]. Pharmacogenetic
studies have demonstrated that genetic differences in CYP2C19 expression contributes to the
inter-individual variability observed in voriconazole pharmacokinetics [147–150]. Genetic
variants in CYP2C19 are common and are known to alter voriconazole metabolism [151].
Using adult doses, paediatric pharmacokinetic studies have described a linear non-saturable
dose-exposure profile for children <5 years of age [152]. However, at higher recommended
doses, children exhibit non-linear voriconazole pharmacokinetics in the majority of children
[153]. As a consequence of differences in the degree of non-linearity in voriconazole
pharmacokinetics between children and adults, paediatric patients require more than twice
the adult dose to achieve comparable blood concentrations [154]. Recently, several
paediatric studies have reported an association between improved patient outcomes and a
voriconazole trough concentration > 1 μg/mL [155–157]. However, high inter-individual
variability makes it challenging to reliably attain this trough target in clinical practice.
Michael et al. [153] reported trough concentrations < 0.1 μg/mL and as high as 16.3 μg/mL
in two toddlers who received the same 7 mg/kg intravenous dose.
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Posaconazole is the most recently developed member of the triazole class and is currently
available as an oral suspension and a delayed-release tablet [158, 159]. The oral absorption
of posaconazole is variable (8–47 %) and may be altered in patients with poor appetite,
nausea, diarrhoea, gastrointestinal disorders, and in patients receiving concurrent acidsuppressive therapies [160]. However, the bioavailability of the posaconazole suspension can
be greatly enhanced when it is administered after a high-fat meal [161]. Administration
every 6 or 8 h with food has been shown to increase posaconazole exposure by 180 % when
compared with once-daily dosing [162]. Notably, the recently approved delayed-release
tablet formulation of posaconazole features improved bioavailability, no food effect and
decreased inter-individual variability when compared with the oral suspension [159, 163,
164]. Similar to the other members of the triazole family, posaconazole inhibits CYP3A4;
however, unlike voriconazole, CYP2C9, CYP2C19 and other CYP isoenzymes are not
affected [165, 166]. Posaconazole has a large volume of distribution at steady state and has
been reported to feature high alveolar penetration with concentrations in pulmonary alveoli
that are approximately 35-fold higher than plasma concentrations [167]. However, the extent
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to which posaconazole crosses the blood–brain barrier is unknown. Up to 20–30 % of the
posaconazole dose is metabolised by uridine diphosphate (UDP)-glucuronosyltransferase
UGT1A4 (the glucuronide conjugates possess minimal antifungal activity) [168] and the
remaining 70–80 % is eliminated unchanged in the faeces [158, 169]. To date, the few
studies available report no obvious pharmacokinetic differences between children and adults
[170].
4.2 Intra- and Inter-Individual Variability
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Triazole pharmacokinetics are influenced by pathophysiologic considerations, including
small bowel resection, graft versus host disease, fluid overload and gastroenteritis [76].
Although specific pharmacokinetic differences exist in certain patient populations,
fluconazole pharmacokinetics are generally less variable than those in other triazole agents
[77, 129]. However, the volume of distribution of fluconazole among children is larger and
marked by increased variability when compared with adult patients [171].
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Itraconazole is an extremely weak base and is only ionised in acidic environments [172]. For
this reason, the capsular formulation of itraconazole features variable dissolution in the
stomach before being absorbed from the small bowel [133]. Additionally, itraconazole is
both an inhibitor and a substrate of the drug transporter P-glycoprotein (P-gp) [173]. The
expression level of P-gp expression found on the apical membrane of mature enterocytes
may play a significant role in itraconazole absorption. This is especially relevant in critically
ill children where P-gp expression has been found to vary up to tenfold [174]. Similarly,
itraconazole is both a substrate and an inhibitor of CYP3A4 [173]. Itraconazole-induced
inhibition of CYP3A4 may result in increased plasma concentrations of other medications
that are metabolised by CYP3A4, including: midazolam, atazanavir, ritonavir, tacrolimus,
cyclosporine (ciclosporin) and others (Table 4) [175].
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The factors contributing to the high inter- and intraindividual variability in voriconazole
pharmacokinetics are poorly understood in children [176]. A multicentre retrospective
review evaluated voriconazole pharmacokinetics among 139 children with invasive
aspergillosis and found that published doses ranged from 3.4 to 23 mg/kg/day [177]. Despite
this wide range in administered voriconazole doses, target troughs >1 μg/mL were rarely
achieved [155, 178, 179]. Moreover, among those children who did achieve target trough
concentrations, the weight-adjusted doses varied widely. In two additional studies recently
conducted among paediatric haematopoietic stem cell transplant patients, less than half of
the patients studied achieved and sustained a therapeutic trough concentration without
individualised voriconazole concentration monitoring and dose adjustment [157, 180]. To
better elucidate the factors affecting voriconazole pharmacokinetics in children, Karlsson et
al. [181] conducted a population pharmacokinetic analysis using data from three studies
conducted among children 2–11 years of age who received a range of single or multiple
intravenous and/or oral voriconazole doses. The authors reported that the CYP2C19
genotype and blood ALT concentration significantly influenced voriconazole clearance
[181]. Similar to other triazole agents, drug-drug interactions can significantly alter
voriconazole exposure [154]. In one such study, the coadministration of phenobarbital
caused a 50 % reduction in the voriconazole Cmax [182].

Clin Pharmacokinet. Author manuscript; available in PMC 2017 August 21.

Stockmann et al.

Page 14

Author Manuscript

Variability in posaconazole pharmacokinetics occurs primarily as a consequence of altered
absorption [170]. This phenomenon is more pronounced in critically ill patient populations,
including those with gastric mucosal alterations such as chemotherapy-associated mucositis
[143]. In one adult study, allogeneic bone marrow transplant recipients had posaconazole
concentrations that were 52 % lower than those measured among non-transplanted febrile
neutropenic patients [183]. The authors also reported a larger inter-individual coefficient of
variation (71–82 %). In a study of 12 children and 194 adults, mean posaconazole plasma
concentrations were comparable [170]. The youngest study participant was 8 years old and
had a mean steady-state posaconazole plasma concentration of 227 ng/mL, which was
comparable with the mean steady-state concentration measured among the oldest paediatric
participant (238 ng/mL) [170]. This finding suggests that posaconazole pharmacokinetics
are similar among older children and adults; however, posaconazole pharmacokinetics have
not been studied among children <8 years of age.
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4.3 Dosing Optimisation
As invasive fungal infections often occur in immunocompromised patients or those with
concomitant bacterial infections, it is challenging to evaluate the clinical response to
antifungal therapy [184]. However, in a study of 28 adult cancer patients with presumed or
proven mould infections, the total daily dose of fluconazole was increased to 1,200, 1,600
and 2,000 mg, which was associated with Cmax values of 51.8, 74.4 and 91.8 mg/L,
respectively [185]. Less than one third of the patients in each dosing group responded to
therapy, implying that the clinical response is not dose—and therefore concentration—
dependent. However, in this study rates of adverse events were observed to increase with
larger doses [185]. Dosages up to 1,600 mg/day were well-tolerated, although larger doses
were associated with neurotoxicity [185].
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Guidelines from the Infectious Disease Society of America (IDSA) recommend that adults
with candidaemia who receive treatment with fluconazole be given a loading dose on the
first day of therapy [186, 187]. In the only paediatric study to date, Piper et al. [188]
evaluated the pharmacokinetics and safety of a 25 mg/kg loading dose among eight infants
<60 days of age with serial fluconazole serum concentration measurements. The authors
found that five of eight (63 %) infants achieved the therapeutic exposure target (AUC24 >
400 mg·h/L) and 100 % achieved a 24-h trough concentration > 8 μg/mL. The three infants
who did not achieve the AUC target were receiving extracorporeal membrane oxygenation
(n = 1), were severely oedematous (n = 1) or immunocompromised (n = 1). Larger loading
doses may be warranted for these special patient populations.

Author Manuscript

There are no published itraconazole pharmacodynamic studies among children with invasive
fungal infections. However, a single study examined the pharmacodynamics of oral
itraconazole among HIV-infected children and adolescents with oropharyngeal candidiasis
[135]. As predicted from murine dose fractionation studies, the pharmacodynamic parameter
that was most closely correlated with the response to treatment was the AUC12 (r = 0.595; P
= 0.01) [135].
In vivo experiments in animal models of invasive candidiasis have demonstrated a strong
relationship between voriconazole exposure and treatment efficacy [21]. Similar to other
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triazoles, the unbound voriconazole AUC/MIC needed to produce a half-maximal antifungal
effect was approximately 25 [21]. For adults with disseminated candidiasis, a voriconazole
AUC/MIC <25 was associated with treatment failure in 40–50 % of the patients studied
[189]. Among patients with invasive aspergillosis, a trough voriconazole concentration > 0.5
μg/mL was associated with a trend toward a higher odds of treatment success (odds ratio 1.5;
95 % CI 0.6–3.4) [190]. In a more recent study of 52 patients who received more than 2,000
days of voriconazole therapy for the treatment of invasive fungal infections, trough
concentrations < 1 μg/mL were associated with a positive outcome in approximately 50 % of
cases as compared to 90 % among patients with troughs ≥1 μg/mL [156]. In a recent
paediatric study, a trough voriconazole concentration < 1 μg/mL was associated with a 2.6fold increased odds of death (95 % CI 1.6–4.8; P = 0.002) [155]. In Monte-Carlo
simulations, the authors found that an intravenous dose of 7 mg/kg or an oral dose of 200 mg
every 12 h would be predicted to achieve a trough > 1 μg/mL in 66 % of patients, although
predicted trough concentrations were highly variable [155]. In another paediatric study, the
clinical outcomes of 30 immunocompromised patients who received a combined 2,135 days
of voriconazole therapy were evaluated [191]. No statistically significant relationship was
found between voriconazole concentrations and overall mortality; however, a higher
percentage of subtherapeutic plasma concentrations was observed in those who died [191].
Among children < 5 years of age, the median dose that yielded trough concentrations > 1
μg/mL was 19 mg/kg every 12 h, which is more than double the current recommended dose
for this age group [155, 191].

Author Manuscript

Few studies have examined the relationship between posaconazole exposure and clinical
efficacy in adults and none have been conducted in children. However, pharmacodynamic
exposure studies have been conducted in murine models of invasive candidiasis and
demonstrated that posaconazole efficacy is maximised with an unbound AUC24/MIC >20–
25 [192]. In one adult study, 67 patients with refractory invasive aspergillosis received
posaconazole and were evaluated for their clinical response to therapy [193]. An exposureresponse relationship was defined, where 80 % of patients in the lowest mean plasma
concentration quartile (< 0.13 μg/mL) experienced treatment failure as compared with 30 %
of patients with steady-state posaconazole concentrations ≥1.25 μg/mL [193]. Further
research is needed to determine if this exposure-response relationship exists in children.
4.4 Therapeutic Drug Monitoring
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Therapeutic drug monitoring is rarely performed for fluconazole, largely owing to its
relatively low pharmacokinetic variability and the lack of studies establishing a correlation
between fluconazole concentrations and clinical outcomes [76, 77, 129]. If therapeutic drug
monitoring for fluconazole is conducted, its extended half-life suggests that the timing of the
sample does not influence the measured concentration once steady state has been reached
[76]. A target AUC24 >400 mg·h/L is recommended to achieve an AUC/MIC > 25 for
Candida species with an MIC at which 90 % of bacteria are inhibited (MIC90)of 8 μg/mL
[194–196].
Numerous itraconazole pharmacodynamic studies have demonstrated strong links between
drug concentrations and clinical efficacy for adult patients with superficial and invasive
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fungal infections [134, 197–200]. Three studies have thus far investigated the utility of
itraconazole therapeutic drug monitoring [197, 199, 201]. In a rabbit model of invasive
pulmonary aspergillosis, Berenguer et al. [197] reported a strong inverse correlation between
itraconazole plasma concentrations and Aspergillus fumigatus tissue density. Moreover,
plasma concentrations <6 μg/mL resulted in a considerable loss of in vivo antifungal activity.
This parallels reports from a study of 21 adults with invasive aspergillosis in which the mean
itraconazole trough measured among patients who responded to therapy was 6.5 μg/mL, as
compared with 4.2 μg/mL among those who did not respond to therapy [199]. In another
study, itraconazole trough concentrations > 1 μg/mL were associated with therapeutic
success among all HIV-infected adult patients who received treatment for cryptococcal
meningitis [201]. In aggregate, these findings suggest that itraconazole therapeutic drug
monitoring should be considered for immunocompromised patients and that trough
concentrations > 1 μg/mL should be targeted.
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Therapeutic drug monitoring for voriconazole is recommended for children with invasive
fungal infections owing to high inter-individual variability and the lack of a well-defined
dose-exposure relationship [202]. In several case series and case reports, voriconazole
plasma concentrations were often reported to be subtherapeutic despite successive dose
increases [154, 176]. Conversely, other children had dramatic increases in their measured
voriconazole concentrations following small dose increases [154]. In a previously mentioned
study conducted among 30 children with immunosuppressive conditions, plasma
concentrations were found to vary widely and 73 % of the children required a dose
adjustment [191]. The authors also reported that elevated trough concentrations (≥5.5
μg/mL) were associated with dermatological and neurological adverse events, although a
similar relationship was not demonstrated for hepatotoxicity [191]. Similarly, Neely et al.
[155] reported that the risk of hepatotoxicity was not significantly associated with
voriconazole dose, AUC, mean plasma concentration, Cmax or minimum plasma
concentration. In aggregate, these findings suggest that target voriconazole trough
concentrations should be> 1 μg/mL to maximise therapeutic effectiveness and<5.5 μg/mL to
minimise the development of toxicity in children.
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Several studies have reported a link between higher steady-state and trough posaconazole
concentrations and improved clinical outcomes [193, 203]. Less than one in four adults who
received posaconazole as salvage therapy for the treatment of invasive aspergillosis
responded to therapy when their mean plasma concentration was < 0.15 μg/mL [193]. In
contrast, three of four patients with a mean posaconazole concentration ≥1.25 μg/mL
responded to therapy [193]. The optimal steady-state, peak or trough posaconazole target is
unclear; however, Andes et al. [143] suggested that a steady-state plasma concentration of at
least 0.5–1.5 μg/mL may be a reasonable target for patients with invasive fungal infections.
Limited data suggest that there is not an association between elevated posaconazole plasma
concentrations and toxicity [170]. In clinical trials, posaconazole was generally welltolerated and associated with fewer adverse drug–drug interactions than other members of
the triazole family [204, 205].
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A major complicating factor in the use of fluconazole is the emergence of resistant fungal
organisms. Multiple epidemiological studies have demonstrated that increased fluconazole
use, both as a therapeutic and as a prophylactic, is associated with increased rates of nonalbicans Candida bloodstream infections [206, 207]. Additionally, several reports have
suggested that the annual incidence of fluconazole-resistant oropharyngeal candidiasis in
patients with AIDS has risen to approximately 5–10 % [208, 209]. Two randomised
controlled trials evaluated prophylactic posaconazole versus fluconazole or itraconazole for
immunocompromised patients at risk for invasive fungal disease and reported an increase in
the frequency of fluconazoleresistant C. albicans during long-term prophylaxis but not in
those who received posaconazole or itraconazole [210]. This differential resistance pattern
among the triazoles may be attributable to a single point mutation in the gene that encodes
the triazole-target lanosterol 14-α-demethylase (ERG11), which has been shown to confer
fluconazole resistance [211]. In contrast, multiple mutations are required to affect
posaconazole and itraconazole susceptibility [121]. Molecular dynamic studies have
demonstrated that the long side chain present on posaconazole and itraconazole stabilises the
binding affinity of these agents to regions surrounding the haeme cofactor CYP51 [212].
Consequently, more mutations are required to destabilise the long side chains of
posaconazole and itraconazole, which are necessary to confer resistance to Candida species
[212]. In the last decade, Aspergillus resistance to the triazole class has increased [213]. A
point mutation in the CYP51A gene has been associated with posaconazole and itraconazole
A. fumigatus resistance [214]. Additionally, a recent study from The Netherlands evaluated
A. fumigatus isolates obtained from eight university hospitals and identified a new
CYP51A-mediated voriconazole resistance mechanism in 21 isolates obtained from 15
patients [215]. Eight patients were diagnosed with voriconazole-resistant invasive
aspergillosis. At 12 weeks after isolation of the highly resistant A. fumigatus strain, four of
eight (50 %) patients had died and two (25 %) had persisting infections. All of the patients
who died had received primary therapy with voriconazole, whereas three of three (100 %)
patients with invasive aspergillosis who received initial treatment with liposomal
amphotericin B were alive at 12 weeks. Perhaps most concerning, the authors recovered
these highly resistant strains from the air of the hospital paediatric ward as well as the
patients’ homes and backyards [215]. As voriconazole yields response rates 15–20 % higher
than non-triazole-containing regimens, it is currently the first-line antifungal agent for
invasive aspergillosis, although monitoring for the spread of these highly resistant strains
must be undertaken to ensure that changes in antifungal selection are guided by local
epidemiology [216, 217].
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4.6 Clinical Recommendations and Prospects for Future Research
The triazoles display time-dependent, concentration-independent fungistatic activity in mice,
although further study is needed to assess whether a clinical relationship between adult
pharmacodynamic targets (e.g. AUC/MIC >25) and clinical outcomes can be defined for
children [24]. Based on limited in vitro and clinical data, fungicidal agents may be
preferable to fungistatic drugs when treating invasive fungal infections in severely
immunocompromised patients [202]. However, definitive randomised trials are needed to
answer this question. There is also a pressing need to evaluate the efficacy of fluconazole
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loading doses in children [188]. Lastly, very few studies have examined the
pharmacokinetics of triazole-based combination therapies [218, 219]. In vitro studies have
demonstrated that the combination of posaconazole and the echinocandin caspofungin
exhibit synergistic antifungal activity against Zygomycetes [218]. Clinically, synergistic
effects have also been described among adult patients treated concurrently with voriconazole
and anidulafungin [219]. Further research is needed to define the pharmacokinetics and
pharmacodynamics of triazole-based combination antifungal therapies in children, as no
such studies currently exist.

5 Echinocandins
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The first prospective trials to evaluate the echinocandins in children began in the early 2000s
and since that time there has been a substantial increase in their use [27, 28, 220]. This is
likely a consequence of their comparable efficacy and improved side effect profile when
compared with other systemic antifungal agents [220]. These drugs exert their antifungal
effects by inhibiting the ß-(1,3)-D-glucan synthase complex, which disrupts cell membrane
permeability. The favourable side effect profile of the echinocandins is attributed to the
absence of a mammalian ortholog of the glucan synthase complex and limited interaction
with phase I/II metabolic enzymes [221].
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Three echinocandin agents are approved for the treatment of invasive fungal infections in
adults, including caspofungin, micafungin and anidulafungin. More recently, caspofungin
and micafungin were approved for use in children [222, 223]. The echinocandins feature
fungicidal activity against many Candida species and fungistatic activity against Aspergillus
[224]. Additionally, the echi-nocandins have been used to successfully treat triazole-resistant
Candida strains and have been reported to feature antifungal activity against biofilms [225,
226]. These agents display similar clinical efficacy for a broad spectrum of invasive yeasts
and moulds, are highly protein bound (97–99 %), are widely distributed (with the exception
of the CSF and urine), and are well-tolerated. Despite these pharmacokinetic and
pharmacodynamic similarities, age-specific metabolic differences influence dosing
requirements for young children. The echinocandins are only available for parenteral
administration, although they feature long half-lives and may be dosed once per day [221].
5.1 Pharmacokinetics and Pharmacodynamics
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As large lipopeptides, the echinocandins exhibit poor oral bioavailability and must be
administered parenterally [224]. The echinocandins exhibit linear pharmacokinetic profiles
post-infusion and are slowly eliminated in the bile and faeces with varying degrees of
degradation products found in the urine. Distribution occurs to most tissues with the
exception of the CSF and the urine [224]. The activity of the echinocandins is attributed to
concentration-dependent (e.g. AUC/MIC or Cmax/MIC) rather than time-dependent killing
against Candida species [221]. Despite glycan synthase expression in other clinical
opportunistic yeasts and moulds, echinocandins are not active against Zygomycetes,
Fusarium species or Scedosporium species. Additionally, they are inactive against
Trichosporon species due to the production of 1,6-D-glucan linkages [221]. None of the
echinocandins are robust substrates for the CYP family or P-gp system, nor do they require
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dosing adjustments in the setting of renal insufficiency [187]. While the echinocandins share
many similarities in their pharmacokinetic and pharmacodynamic profiles, differences do
exist. Caspofungin is subject to hydrolysis or N-acetylation, whereas micafungin is
metabolised by catechol-O-methyltransferase and anidulafungin is chemically degraded
[11].
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For caspofungin, true pharmacokinetic steady state is estimated to require 2–3 weeks of
dosing, although the majority of accumulation will occur within the first few days of
administration [27]. After initial administration, caspofungin distributes to the kidney, lung,
spleen and liver, with 35 % of the total dose residing hepatically at 24 h post-infusion [227].
A weight-based dosing regimen of caspofungin in children 2–11 years and two adolescents
was found to be inadequate, leading to a significantly lower AUC24 and half-life than in
adults receiving 50 mg/day [27]. However, using a body surface area (mg/m2) dosing
regimen generated very similar AUC24 values when compared with adults after multiple
doses (i.e. steady state). For both children and adolescents, dosing scaled to body surface
area effectively controls for the variation in caspofungin clearance across the paediatric age
range. However, it is not possible to achieve an identical AUC24, peak and trough profile to
that of adults as the half-life of caspofungin is 30–40 % shorter in children. This may be
driven by higher intrinsic transporter expression, increased blood flow and/or relative liver
size [28].
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Similar to caspofungin, the pharmacokinetic profile of micafungin is influenced by age [31,
228]. Children ≤8 years of age exhibit higher micafungin clearance (up to 150 %), have an
increased volume of distribution at steady state, and significantly shorter half-life than older
children [28]. These findings were corroborated in a recent analysis of paediatric patients
from a double-blind, randomised, multinational non-inferiority trial [228]. Micafungin and
caspofungin exhibit similar Cmax and half-life profiles in children.
Compared to the FDA-approved echinocandins, relatively little is known about
anidulafungin. From the few studies of anidulafungin in children, there are some notable
differences in comparison with caspofungin and micafungin. Anidulafungin has a lower
capacity for protein binding, a larger volume of distribution and a longer half-life [229].
Additionally, a dose-escalation study in children (2–11 years of age) and adolescents (12–17
years of age) found that dosing by weight generated similar pharmacokinetic parameters to
those in adults [229]. Additionally, anidulafungin rapidly reaches steady-state concentrations
(after two doses) as compared with the other echinocandins [11].
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The echinocandins exhibit a concentration-dependent post-antifungal effect, which appears
to be inversely related to the duration of exposure [223]. This seems to be a corollary to the
‘paradoxical effect’ where Candida species survive and continue to grow when exposed to
high echinocandin concentrations. However, this has been demonstrated in vitro and the
clinical relevance is not yet known [230, 231].
5.2 Intra- and Inter-Individual Variability
For the two FDA-approved echinocandins, the main source of pharmacokinetic variability in
children is their decreasing clearance with increasing age [221]. Additionally, the underlying
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disease status of the patient and concomitant medications also contribute to inter- and intraindividual variability. Relatively small sample sizes in published paediatric studies make it
difficult to assess differences in treatment outcomes by age, sex and race/ethnicity [232].
5.3 Dosing Optimisation
Current paediatric indications and dosing recommendations for the FDA-approved
echinocandins are listed in Table 1. The echinocandins do not require dosing adjustments for
patients with renal failure. However, in patients with severely compromised hepatic function
a decrease in dosage is recommended for caspofungin and may be considered for
micafungin [187, 221].
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Micafungin has recently been approved for the treatment of candidaemia and antifungal
prophylaxis in children ≥4 months of age [222]. For the treatment of oesophageal
candidiasis among patients <30 kg, 3 mg/kg (2.5 mg/kg if < 30 kg) with a daily maximum of
150 mg is recommended. For other sites (not including the CNS) of infection, 2 mg/kg with
a maximum daily dose of 100 mg is recommended. This latest recommendation parallels
experience from previous studies that used weight-based dosing and similar amounts of
micafungin [221, 233]. However, the recommended dose for non-oesophageal candidaemia
(2 mg/kg) results in a 25 % lower Cmax and 50 % lower AUC for children < 5 years of age
[234]. However, Undre et al. [234] caution that no children failed therapy due to a lack of
efficacy and their sample size prohibited their ability to establish definitive paediatric dosing
recommendations. Additionally, the authors hypothesised that younger children are likely to
have a higher free fraction of micafungin due to developmental changes in protein binding
[235]. In an open-label study assessing micafungin safety and pharmacokinetics, micafungin was well-tolerated in infants with suspected invasive CNS candidiasis who received
up to 10 mg/kg/day [236, 237]. This finding is in agreement with 2009 IDSA guidelines,
which recommend paediatric micafungin doses of 2–4 mg/kg/day [187].
As with micafungin, early studies of caspofungin indicated that children and adolescents
require higher doses than adults [27]. Dosing caspofungin based on body surface area rather
than weight led to consistent achievement of plasma concentrations that correlated with
efficacy in adults [187]. Unlike the other echinocandins, the pharmacokinetics of
caspofungin necessitate a loading dose. FDA dosing recommendations for children ≥3
months are based on body surface area. The loading dose is 70 mg/m2 on day 1 with a
maintenance dose of 50 mg/m2 up to a maximum of 70 mg/m2 if required.
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Anidulafungin is not approved for use in paediatric patients in the USA or Europe and
limited data exist regarding its use in children. However, like micafungin and caspofungin,
its safety and efficacy profiles appear promising [238, 239]. Dosing by weight has led to
similar pharmacokinetic profiles as found in adults and, in contrast to the other
echinocandins, anidulafungin clearance does not depend on age [223].
Small sample sizes among paediatric studies have made assignation of echinocandin-specific
adverse drug reactions imprecise. Many of the reported side effects are consistent with adult
data, including gastrointestinal disturbances (vomiting, diarrhoea, fever, nausea, abdominal
pain) and transaminase elevation. Discontinuation due to these side effects is infrequent
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(3.8 % in a substudy of micafungin use in paediatric patients < 16 years of age) relative to
other classes of antifungals and infusion-related hypersensitivity reactions are rare [233].
5.4 Therapeutic Drug Monitoring
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At present, therapeutic drug monitoring is not recommended for the echinocandins due to a
lack of evidence that suggests that routine plasma concentration monitoring provides utility
in clinical practice [202, 240]. Nonetheless, in a case of neonatal meningitis, therapeutic
monitoring of caspofungin concentrations in the CSF was found to be useful in establishing
caspofungin concentrations that were sufficient to sterilise the CSF [241]. Additionally,
monitoring may be considered when cyclosporine is coadministered, which has been
reported to increase caspofungin and anidulafungin plasma concentrations due to diminished
hepatic uptake [242]. Conversely, cyclosporine concentrations may become elevated when
administered with micafungin. A similar pattern has been reported for sirolimus and
nifedipine, which also occurs as a consequence of mild CYP3A inhibition [243]. Tacrolimus
concentrations may be decreased with the concurrent use of caspofungin; however, this has
not been reported to cause toxicity [244]. Agents known to induce hepatic metabolism, such
as rifampin (rifampicin), can lead to significant decreases in caspofungin plasma
concentrations [242].
5.5 Drug Resistance
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Echinocandin resistance is rare and has been reported in <1.2 % of Candida species isolated
in a recent global surveillance study [245, 246]. However, evidence of clinically resistant
Candida with MICs within the susceptible and intermediate breakpoints has prompted a
reassessment of echinocandin susceptibilities [247]. Although multiple potential
mechanisms of resistance have been demonstrated in vitro, clinically relevant echinocandin
resistance for Candida species is driven primarily by ‘hot spot’ mutations in the β-1,3-Dglucan synthase (encoded by the fks1/fks2 genes) target enzyme [248, 249]. The former
breakpoint MIC of ≤2 deemed as ‘susceptible’ for all Candida species and the echinocandin
class has been revised [247]. Currently, MICs >0.5 μg/mL are considered resistant for
anidulafungin, caspofungin and micafungin against C. albicans, C. tropicalis and C. krusei
and >0.4 μg/mL for C. parapsilosis. C. glabrata resistance may be on the rise and is defined
at values >0.12 μg/mL for micafungin and > 0.25 μg/mL for anidulafungin and caspofungin.
Clinical breakpoints have not been defined for Aspergillus species [245]. Cross-resistance
with the polyenes or triazoles has not been reported. Rather, the echinocandins are
considered first-line agents for the treatment of fluconazole-resistant strains of Candida
[221]. Resistance to one echinocandin can generally be interpreted as resistance to the entire
class [246, 247].
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5.6 Clinical Recommendations and Prospects for Future Research
The use of echinocandins in paediatric patients has substantially increased over the last 5
years [220, 232]. The echinocandins offer comparable efficacy, an improved safety profile,
and advantages in treating resistant fungal infections and refractory biofilms. However, the
evolving story of drug-drug interactions and uncertainties regarding pharmacodynamic
exposure-response relationships are two key areas where there are still many unanswered
questions. A recent survey of prescribing practices among Japanese physicians in paediatric
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patients with invasive fungal infections found that physicians were more likely to use
antifungals based on perceptions of potency rather than on safety. Micafungin was the most
frequently prescribed [250]. More research is needed to ensure that paediatric echinocandin
dosing regimens are optimised for therapeutic effectiveness without compromising patient
safety or tolerability.

6 Summary and Conclusions
The introduction of several new systemic antifungal agents in the last two decades has
expanded our therapeutic arsenal for the treatment of invasive fungal infections. However,
with these new agents comes a pressing need to understand their pharmacokinetic properties,
clinical effects and associated toxicities.
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The pharmacokinetic and pharmacodynamic characteristics of systemic antifungal agents
have been well-studied in adults; however, paediatric-specific data are limited. Extensive in
vitro and animal model studies have demonstrated strong relationships linking antifungal
exposure to treatment efficacy. Our understanding of these principles is increasing and has
highlighted the utility of therapeutic drug monitoring for flucytosine, itraconazole,
voriconazole and posaconazole. However, further research is needed to define the
pharmacokinetics, pharmacodynamics and clinical utility of combination antifungal
therapies in children.
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From all of the studies discussed in this review, it must be concluded that—in the absence of
data—antifungal pharmacokinetics in children cannot be assumed to mirror adult
pharmacokinetic parameters. However, antifungal pharmacodynamic targets are remarkably
similar among all age groups, different drugs within the same class, and even across species.
These pharmacodynamic targets provide clinicians the opportunity to predict treatment
efficacy.
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Key Points
The development of dosing recommendations for children with invasive fungal infections
is complicated by non-linear growth and the maturation of organ function.
Pharmacokinetic and pharmacodynamic relationships established in vitro and in murine
models have been confirmed in paediatric clinical trials for several antifungal agents.
Therapeutic drug monitoring should be considered for antifungal agents that exhibit high
inter-individual variability and a strong association between plasma concentrations and
efficacy and/or toxicity (e.g. voriconazole).
Further research is need in the design and optimisation of combination antifungal
regimens.
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Fig. 1.

The four most common classes of systemic antifungal agents used in the treatment of
invasive fungal infections and their mechanisms of action
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Antifungal pharmacodynamics in murine models of invasive candidiasis. a Amphotericin B
dose fractionation studies for three dosing intervals and the log10 colony-forming units per
gram of kidney in a neutropenic mouse model of disseminated candidiasis (data from Andes
et al. [15]). b Flucytosine dose fractionation studies for four dosing intervals and the mean
Candida density in the kidneys of neutropenic mice (data from Andes and van Ogtrop [12]).
c Fluconazole dose fractionation studies for three dosing intervals and mean fungal density
in the kidneys of mice with invasive candidiasis (data from Louie et al. [13]). d
Anidulafungin dose fractionation studies for four dosing intervals and the mean change in
Candida density in the kidneys of neutropenic mice with invasive candidiasis (data from
Andes [24]). CFU colony-forming units, qx hrs every x hours
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US FDA-approved agents for the treatment of invasive fungal infections in children
Pharmacological agent

Author Manuscript

Approved indication

Approved dose

Fluconazole

Treatment of oropharyngeal and oesophageal candidiasis and
cryptocococcal meningitis

Initial: 6 mg/kg/dose od
Maintenance: 3–12 mg/kg/dose
od Maximum daily dose: 600
mg/day

Itraconazole

Treatment of blastomycosis (pulmonary and extrapulmonary),
histoplasmosis (including chronic cavitary pulmonary disease and
disseminated, non-meningeal histoplasmosis) and aspergillosis
(pulmonary and extrapulmonary) in patients who are intolerant of or
who are refractory to amphotericin B therapy

3–5 mg/kg/dose od

Posaconazole

Treatment of oropharyngeal candidiasis, including oropharyngeal
candidiasis refractory to itraconazole and/or fluconazole

400 mg bid

Voriconazole

Treatment of invasive aspergillosis; candidaemia in non-neutropenic
patients; disseminated Candida infections in skin, the abdomen,
kidney, bladder wall and wounds; oesophageal candidiasis; and
serious fungal infections caused by Scedosporium apiospermum and
Fusarium spp., including Fusarium solanì, in patients intolerant of or
refractory to other therapies

9 mg/kg/dose bid
Maximum single dose: 350
mg/dose

Caspofungin

Empirical therapy for presumed fungal infections in febrile,
neutropenic patients; treatment of candidaemia and the following
Candida infections: intra-abdominal abscesses, peritonitis and pleural
space infections; treatment of oesophageal candidiasis; and treatment
of invasive aspergillosis in patients who are refractory to or intolerant
of other therapies

Initial: 70 mg/m2/dose od
Maintenance: 50 mg/m2/dose
od Maximum daily dose: 70
mg/m2/day

Micafungin

Treatment of patients with candidaemia, acute disseminated
candidiasis, Candida peritonitis and abscesses; treatment of patients
with oesophageal candidiasis

2 mg/kg od
Maximum daily dose: 100
mg/day

Treatment of potentially life-threatening invasive fungal infections:
aspergillosis, cryptococcosis, North American blastomycosis,
systemic candidiasis, coccidioido-mycosis, histoplasmosis,
zygomycosis, including mucormycosis due to susceptible species of
the genera Absìdìa, Mucor and Rhizopus, and infections due to
related susceptible species of Conìdìobolus and Basìdìobolus, and
sporotrichosis

Initial: 0.25–0.5 mg/kg/dose od
Maintenance: 0.25–1 mg/kg/
dose od Maximum daily dose:
1.5 mg/kg/day

Liposomal amphotericin B
(AmBisome)

Empirical therapy for presumed fungal infection in febrile,
neutropenic patients; treatment of cryptococcal meningitis in HIVinfected patients; treatment of patients with Aspergillus, Candida
and/ or Cryptococcus infections refractory to amphotericin B
deoxycholate, or in patients in whom renal impairment or
unacceptable toxicity precludes the use of amphotericin B
deoxycholate; and treatment of visceral leishmaniasis

3–5 mg/kg/dose od

Amphotericin B lipid complex
(Abelcet®)

Treatment of invasive fungal infections in patients who are refractory
to or intolerant of conventional amphotericin B therapy

3–5 mg/kg/dose od

Amphotericin B colloidal
dispersion (Amphotec®)

Treatment of invasive aspergillosis in patients where renal
impairment or unacceptable toxicity precludes the use of
amphotericin B deoxycholate in effective doses, and in patients with
invasive aspergillosis where prior amphotericin B deoxycholate
therapy has failed

3–1 mg/kg/dose od

Treatment of serious infections caused by susceptible strains of
Candida and/or Cryptococcus

50–150 mg/kg qid

Azoles

Echinocandins

Polyenes
Amphotericin B deoxycholate
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Pyrimidine analogues
Flucytosine

bid twice daily, od once daily, qid four times daily
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Structural and pharmacokinetic properties of amphotericin B formulations among adults with invasive fungal
infections
Property

Amphotericin B deoxycholate

Lipidic formulations
Amphotericin B
lipid complex

Amphotericin B
colloidal
dispersion

Liposomal amphotericin B

Formulation properties
Size (nm)

0.035

1,600–11,000

120–140

80

Structure

Micelles

Ribbon-like

Disk-like

Liposomes

1.0

5.0

5.0

5.0

Maximum plasma
concentration (mg/L) [mean ±
SD]

5.36 ± 0.82

1.58 ± 0.32

7.66 ± 4.51

46.7 ± 2.81

Minimum plasma concentration
(mg/L) [mean ± SD]

0.34 ± 0.07

0.24 ± 0.08

0.37 ± 0.12

26.4 ± 4.99

Area under the concentration–
time curve from time 0 to 24 h
(mg·h/L) [mean ± SD]

17.4 ± 1.21

11.8 ± 3.09

20.4 ± 4.10

887 ± 59

Apparent volume of
distribution at steady state (L/kg)
[mean ± SD]

0.81 ± 0.10

6.35 ± 1.25

3.61 ± 0.64

0.10 ± 0.01

Total plasma clearance (L/kg/h)
[mean ± SD]

0.041 ± 0.00

0.315 ± 0.11

0.187 ± 0.04

0.001 ± 0.00

Plasma pharmacokinetic properties
Dose (mg/kg)

Author Manuscript

Pulmonary pharmacokinetic properties
Dose (mg/kg)

Author Manuscript

1.0

5.0

5.0

5.0

Concentration in lung tissue
(μg/g) [mean ± SD]

2.71 ± 1.22

16.26 ± 1.62

6.29 ± 1.17

6.32 ± 0.57

Concentration in epithelial
lining fluid (mg/L) [mean ± SD]

0.44 ± 0.13

0.90 ± 0.28

0.68 ± 0.27

2.28 ± 1.43

Concentration in pulmonary
alveolar macrophages (mg/L)
[mean ± SD]

8.92 ± 2.84

89.1 ± 37.0

5.43 ± 1.75

7.52 ± 2.50

Plasma concentration (mg/L)
[mean ± SD]

1.82 ± 0.07

0.93 ± 0.03

0.85 ± 0.01

62.90 ± 0.99

CSF concentration (mg/L)
[mean ± SD]

0.023 ± 0

0.022 ± 0

0.014 ± 0.007

0.024 ± 0.001

Brain concentration (μg/g)
[mean ± SD]

0.18 ± 0.03

0.27 ± 0.02

0.22 ± 0.02

1.99 ± 0.33

Tissue penetration properties

Data from Hiemenz and Walsh [251], Groll et al. [252, 253]

CSF cerebrospinal fluid
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Pharmacokinetic properties of fluconazole, itraconazole, voriconazole and posaconazole in adults
Property

Fluconazole

Itraconazolea

Voriconazole

Posaconazole

Dose

6–12 mg/kg/day

200 mg bid

6 mg/kg q12 h for 2
doses, then 4 mg/kg
q12 h

600–800 mg/day in
divided doses

Route of administration

IV infusion, PO
capsules, PO
solution

IV infusion, PO
capsules, PO
solution

IV infusion, PO
capsules, PO
suspension

PO suspension

Oral bioavailability (%)

>80

50

90

Protein binding (%)

11–13

>99

58

98–99

6–20

0.5–2.3

3.0–4.6

1.5–2.2

400–800

29.2

20.3

8.9

Terminal elimination half-life (h)

22–35

24–42

6

25

Unchanged drug in urine (%)

80

1–10

<2

<2

Primary route of metabolism

Hepatic (minor)

Hepatic

Hepatic

Hepatic (moderate)

Primary route of elimination

Renal

Hepatic

Renal

Faeces

CSF penetration (%)

80

<10

60

–

Vitreous penetration (%)

28

10

38

26

Formulation properties

Pharmacokinetic properties
Maximum concentration (μg/L)

Author Manuscript

Area under the concentration– time
curve (mg·h/L)

Bodily fluid penetration properties

Data from Lewis [117] and Lipp [158]

bid twice daily, CSF cerebrospinal fluid, IV intravenous, PO oral, q12 h every 12 h
a

Data are for the oral solution formulation of itraconazole
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Fluconazole, itraconazole, voriconazole and posaconazole drug–drug interactions
Property

Fluconazole

Itraconazole

Voriconazole

Posaconazole

X

X

X

X

X

X

X

X

X

X

X

X

X

Decreased absorption of azoles
Antacids

X

Didanosine, oral

X

Histamine H2 receptor antagonists
Omeprazole

X
X

X

Sucralfate
Increased metabolism of azoles
Carbamazepine

X

Isoniazid

Author Manuscript

Phenobarbital

X

X

X

Phenytoin

X

X

X

X

Rifampin (rifampicin)

X

X

X

X

Ado-trastuzumab emtansine

X

X

X

Alfuzosin

X

X

X

Aliskiren

X

Alprazolam

X

Apixaban

X

X

X

Increased plasma concentration of coadministered drug

Astemizole

X

Atazanavir

X

Atorvastatin

X

Author Manuscript

Avanafil

X

X

X

Axitinib

X

X

X

Barbiturates
Bosutinib

X
X

Cabozantinib
Cisapride

X

Citalopram

X

Conivaptan

X

Crizotinib

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

Darunavir

X

Dihydroergotamine
Dofetilide
Dronedarone

X

X

X

X

X

X

X

X

X

X

Author Manuscript

Efavirenz

X

Eletriptan

X

X

Eplerenone

X

X

X

Ergoloid mesylates

X

X

X

Ergonovine

X

X

X
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Fluconazole

Author Manuscript

Itraconazole

Voriconazole

Posaconazole

Ergotamine

X

X

X

Everolimus

X

X

X

Halofantrine

X

X

X

Imatinib

X

X

X

X

X

X

X

X

X

X

X

X

Ivabradine

X

Lapatinib
Lomitapide

X

Lopinavir

X

Lovastatin

X

Lurasidone
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Macitentan

X

Methadone

X

Methylergonovine

X

Midazolam

X

Mifepristone

X

X

X

X

X

X

X
X

X

X

X

Nevirapine

X

Nilotinib

X

X

X

Nisoldipine

X

X

X

X

X

X

X

X

X

Ospemifene

X

Pimozide

X

Pomalidomide
Proton pump inhibitors

X

Quinidine

X

X

X

X

Ranolazine

X

X

X

X

X

X

X

Regorafenib
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Rifamycin derivatives

X

Ritonavir

X

Rivaroxaban

X

X

X

Salmeterol

X

X

X

Silodosin

X

X

X

Simvastatin

X

X

X

X

X

Sirolimus
St John’s wort

X

Tamsulosin

X

Terfenadine

X
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X

X

X

X

X

X

X

X

X

X

X

X

X

X

Topotecan

X

Toremifene

X

Triazolam

X

Ulipristal
Vemurafenib

X

X

Ticagrelor
Tolvaptan

X

X
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Property
Vincristine, liposomal
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Fluconazole

Itraconazole

Voriconazole

Posaconazole

X

X

X
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Data from Hoesley and Dismumkes [254], Dismukes [255], Katz [256] and the Lexi-Comp Drug Interactions Handbook and Drug Interactions
Software [257]
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